IZOTROPIC ORD SHS
IZOZF
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.73M
Close$
$-0.03
126.4% downside
Current Fair Value
126.4% downsideOvervalued by 126.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.73 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 2.42 |
| Outstanding Shares | 69,724,679 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -5.01 |
|---|---|
| PEG | -19.61 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$2.03 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Izotropic Corporation
5 employees
CEO: Robert Louis Thast Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT br...